Research programme: synthetic antimicrobial peptidomimetics - Lytix Biopharma
Alternative Names: LTX100; LTX200Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Lytix Biopharma
- Class Amino acids peptides and proteins
- Mechanism of Action Cell membrane modulators; Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Bacterial infections; Mycoses
Highest Development Phases
- No development reported Bacterial infections; Mycoses
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Norway (Topical)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Mycoses in Norway (Topical)
- 04 Feb 2011 Research programme: synthetic antimicrobial peptidomimetics - Lytix Biopharma is available for licensing as of 23 Oct 2006. http://www.lytixbiopharma.com